Dr. Theodore Ikechukwu Otti, M.D. Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1035 Bellevue Ave Ste 315, Richmond Heights, MO 63117 Phone: 314-683-6110 Fax: 314-485-2136 |
News Archive
Eli Lilly and Company and Boehringer Ingelheim announced today that Cymbalta/Xeristar (duloxetine hydrochloride)(+) has been granted marketing authorization by the European Commission for the treatment of major depressive episodes.
Coronary atherosclerosis - a hardening of the arteries due to a build-up of fat and cholesterol - can lead to heart attacks and other forms of coronary heart disease (CHD). Lowering low-density lipoprotein (LDL), or "bad" cholesterol, reduces the risk of CHD, and researchers found that lowering LDL beginning early in life resulted in a three-fold greater reduction in the risk of CHD than treatment with a statin started later in life, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.
Researchers conducting a large international study of progressive multiple sclerosis (MS) examined the impact of the global outbreak of coronavirus disease 2019 (COVID-19) on their study participants.
Scientists have identified some of the first genetic triggers for cancer as mutations in specific oncogenes or tumor suppressor genes. Full-blown tumors and metastatic cancers, however, often exhibit many genetic mutations, sometimes dozens in a given tumor. An important scientific question, and one with significant clinical implications, has been what happens after the initial mutation that leads to dangerous later-stage cancers with multiple damaged genes.
Before patients get their clogged heart arteries re-opened, they may want to ask their doctor just how many such procedures he or she has done, a new study finds. The answer may make a big difference in each patient's risk of suffering a major setback before leaving the hospital.
› Verified 6 days ago